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1. Introduction  
Obesity is a process by which excess energy accumulates and results in increasing fat 
deposition in various parts of the body. Obesity is associated with economic, social, and 
lifestyle factors, and is commonly induced by imbalanced energy intake and consumption of 
high calorie foods or low physical activity. Obesity is a worldwide issue in public health that 
significantly increases the risk for type 2 diabetes, metabolic syndrome, atherosclerosis, and 
cardiovascular disease.  
Body weight increases with aging in both genders, irrespective of the baseline weight in 
normal and obese individuals [1]. This increase in body weight is attributed to a reduction 
in energy expenditure with decreased physical activity. The global prevalence of obesity has 
been reported to be higher in females than males [2]. A US population survey estimated that 
approximately two thirds of women 40 - 60 years of age are overweight or obese [3].  
In addition to aging, the menopause is considered an important factor for contributing to 
altered adiposity in women. Menopause is defined as a decline in endogenous estrogen 
production from the ovaries, and clinically represents cessation of menstruation and loss of 
fertility. Estrogen loss is the most significant event impacting a variety of physiologic and 
psychological changes in women. In the peri- or postmenopausal period, a change in 
adiposity has been well described. Weight gain during the menopausal transition has been 
scrutinized as a critical factor to midlife body weight in women [1]. Several observational 
studies have shown increased weight gain during the menopausal transition [4, 5]. A 
number of clinical trials have demonstrated a significant association between menopausal 
status with changes in anthropometry, blood pressure, lipid profile, and glucose/insulin 
metabolism [6-11], which can be linked to increased cardiovascular morbidity and mortality 
during the postmenopausal period [12].  
Given the collective evidence on the change in adiposity across the menopausal transition, 
the roles of sex hormones, especially estrogen, are of increased interest in understanding the 
regulation of adiposity. This review discusses the association between estrogen and 
adiposity, and the interaction of estrogen with other biological metabolites and substances 
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involved in obesity. In addition we summarize evidence for the effect of postmenopausal 
hormone therapy (HT) on changes in body composition.  
2. Adipose tissue 
Adipose tissue has a vital role in the lives of mammals. The primary function of adipose 
tissue is to store excess energy within the body in the form of free fatty acids (FFAs) and 
heat production. However, adipocytes are currently regarded as an independent endocrine 
organ since the metabolic and endocrine actions have been revealed.  
In mammals, two types of adipose tissue exist (white adipose tissue [WAT] and brown 
adipose tissue [BAT]) [13]. WAT represents the major component of adipose tissue and 
provides most of the total body fat [13]. Moreover, WAT is the main source of FFAs that are 
available as energy substrates for generation through oxidative phosphorylation of 
adenosine triphosphate (ATP) high-energy bonds [13, 14]. Excess WAT in the upper parts of 
the body (android type obesity) represents a strong risk factor for some inflammatory 
pathologies [15]. In contrast, accumulation of WAT in lower body parts (gynecoid type 
obesity) is not associated with metabolic complications [13, 15].  
In contrast to WAT, BAT participates in energy expenditure from non-oxidative 
phosphorylation in the form of heat for cold adaption [16]. The uncoupling of 
phosphorylation in BAT is attributed to the activity of uncoupling protein-1, which is 
expressed on the mitochondrial membrane, by creating a proton leak that depletes the 
electrochemical gradient needed for oxidative phosphorylation [14, 16]. BAT represents a 
smaller number of fat cells that have a rich vascular supply, which can respond more 
rapidly to sympathetic nervous system stimulation, and elicits heat production, rather than 
ATP production from nonshivering cold adaptive thermogenesis [14, 16]. In humans, BAT 
helps to maintain body temperature in newborns, but BAT regresses with increasing age 
and is completely lost in adulthood [17, 18]. Recently, Virtanen et al. studied BAT deposition 
in healthy adults using the glucose analogue, 18F-flurodeoxyglucose, uptake by PET and 
computed tomography [18]. Metabolically-active BAT depots in paracervical and 
supraclavicular adipose tissue, which can be induced in response to cold and sympathetic 
nervous system activation, has been reported [14, 16, 18]. The presence of BAT in human 
adults is of potential interest in understanding the mechanism of obesity, and may provide a 
rationale for pharmacologic and gene expression manipulation to combat human obesity 
[14, 18, 19].    
3. Deposition and distribution of adipose tissue 
Deposition of the fat mass has a different pattern between the genders. Young males have 
little subcutaneous fat and do not show a central-peripheral difference [20], whereas women 
of reproductive age have more subcutaneous fat than men at all measured subcutaneous 
regions [21]. In addition, with an increasing severity of obesity, adipose tissue thickness is 
higher in the central regions in men, but women exhibit a peripheral deposition [20]. This 
pattern of fat deposition is altered in women across the menopausal transition; specifically, 
the total amount of body fat increases, and the peripheral fat shifts around the abdomen. 
Furthermore, the change in visceral adipose tissue has been ascribed to both chronologic 
aging and menopause [22, 23]. The results from a clinical study with 156 healthy women 
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during 4 years of follow-up showed an increase in visceral adipose tissue and total body 
fat, and a 32% reduction in fat oxidation during the menopausal transition [4]. In the 
study, the subcutaneous adipose tissue increased in accordance with age independent of 
menopausal status, while the findings of increased visceral adipose tissue and total body 
fat were noted only in postmenopausal women. This distinctive physiologic change in 
amount and distribution of fat in women is noteworthy because the central fat deposition 
has a more deleterious effect on the development of cardiovascular and metabolic disease 
[24, 25].  
Although the exact mechanism regarding fat redistribution after menopause remains 
unclear, the phenomenon with declining estrogen level may be due to alterations in adipose 
tissue metabolism [4]. Several studies have shown that estrogen directly promotes 
subcutaneous fat accumulation [26], and the loss of estrogen by menopause is associated 
with an increase in central fat. Several longitudinal studies lend support in suggesting that 
estrogen plays an important role in regulating body fat distribution. Postmenopausal 
women who receive estrogen replacement have significantly lower waist-to-hip ratios and 
less visceral adipose tissue than women who have never received estrogen replacement 
therapy [27, 28].  
In experimental studies, 17ǃ-estradiol (E2) has been shown to regulate adipose tissue by 
increasing the number of adipocytes through effects on proliferation and differentiation [29, 
30]. The number and size of adipocytes is a determining factor for adiposity, and the 
adipocyte size is balanced by lipogenesis and the lipolysis pathway. Palin et al. have found a 
direct regulatory effect of E2 on the expression of lipoprotein lipase (LPL) and hormone-
sensitive lipase (HSL) in human subcutaneous abdominal adipose tissue [31]. LPL is a major 
modulator of lipid deposition as triglycerides into adipocytes, and HSL is the rating-limiting 
enzyme involved in the process of lipolysis. Therefore, the direct effect of estrogen on these 
enzymes might lead to fat redistribution in postmenopausal women. 
As other mechanisms suggest, the role of the estrogen receptor (ER) is focused on estrogen-
related action on the regulation of adiposity. Adipocytes express two main subtypes of ERs 
(alpha [ERǂ] and beta [ERǃ]). ERǂ was discovered first, and the biological effects of ERǂ on 
adiposity have been thoroughly described. ERǂ is considered to be essential for genomic 
actions of E2 on the regulation of body fat [32]. Because the hypothalamic nuclei that 
regulate energy homeostasis express ERǂ, E2 action could affect adiposity [33-35]. An 
animal study conducted by Heine et al. demonstrated that glucose intolerance, hypertrophy, 
and hyperplasia of adipocytes are induced in ERǂ knockout mice [36], thus supporting a 
critical role of ERǂ in determining adiposity.  
In contrast, the biological implications of the more recently discovered ERǃ have been less 
revealing than ERǂ. The binding affinity of estrogen to ERǂ and ERǃ is known to be 
similar, but the two subtypes of ER only have 56% identity in the ligand binding domain 
[26, 37, 38]. Therefore, different or competitive roles between both ERs have been 
repeatedly suggested. Naaz et al. studied the role of ERǃ in adipose tissue [39] in mice 
with ERǂKO. When compared to the results generated in ERǂKO mice, it was shown that 
removing E2/ERǃ signaling induced a decrease in body weight, the amount of fat, and 
adipocyte size. Therefore, the authors suggested a potential role for ERǃ in regulating 
adiposity, as well as ERǂ, but with opposing actions. Thus, the roles for ERs in adipocytes 
might be an interesting target to further elucidate the estrogen effects on regulating 
adiposity. 
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4. Proinflammatory cytokines production 
Obesity is a low grade systemic inflammatory state; several studies have addressed 
adipocyte-related mechanisms involved in regulating proinflammatory [15, 40] and 
adipocyte-specific cytokines. Systemic chronic inflammation is due to an inflammatory 
response in adipose tissues that are under quick expansion, and in which macrophages and 
adipocytes are activated and stimulate the production of proinflammatory cytokines and 
adipokines [41]. Visceral WAT is considered a main source of inflammation related to 
obesity. Obese subjects with higher visceral fat exhibit monocyte-chemotactic protein 
(MCP)-1 expression and infiltration of macrophages in visceral fat compared to 
subcutaneous fat [42]. Also, several in vivo studies have shown higher levels of plasminogen 
activator inhibitor (PAI)-1, IL-6, and TNF-ǂ in visceral obesity [43, 44].     
Recent studies have shown the inhibitory role of estrogen to the inflammatory response in 
adipose tissue, and cardiovascular and nervous systems [35]. ERǂ is located in cytokine-
producing cells, such as macrophages and microglia, and several in vitro studies have reported 
that E2/ ERǂ decreases the number of pro-inflammatory cytokines [35, 45, 46]. Another in vivo 
study has demonstrated that both ERǂ and ERǃ regulate proinflammatory cytokine and 
chemokine production through E2-dependent and independent mechanisms [47].  
Because energy expenditure is related to inflammation, a role for nuclear receptor kappa B 
(NF-κB) has been suggested. NF-κB is a protein complex that controls transcription factor, 
and is known to have a crucial role in regulating immune responses to infection or stress. 
NF-κB induces the transcription of inflammatory cytokines, such as TNF-ǂ, IL-1, IL-6, and 
MCP-1 [41]. In the classical pathway, NF-κB is mediated through IKKǃ-induced 
phosphorylation and proteasome-mediated degradation of IkBǂ [48]. The other pathway is 
the activation by hypoxia in the absence of IkBǂ degradation, a pathway in adipocytes and 
macrophages which contributes to chronic inflammation in the adipose tissues of obese 
subjects [41, 49]. Limited evidence has proposed an inhibitory effect of E2 via ERǂ on NF-κB 
[50, 51], which partially explains the anti-inflammatory properties of estrogen.     
5. Adipokine expression/secretion 
Adipokines are a family of cytokines which include leptin, resistin, adiponectin, and TNF-ǂ 
and are primarily secreted from adipocytes. These adipokines are released from different 
tissues and organs, and are not exclusively produced by WAT [14, 52].  
Leptin, the product of the ob gene, has been shown to be a key metabolic hormone in 
regulating appetite body weight and energy homeostasis [53, 54]. In humans, circulating 
leptin levels have a parallel correlation with the amount of body fat. In addition, serum 
levels of leptin have been shown to be higher in women than men [55]. This finding has 
been hypothesized to be due to a different pattern in fat deposition between the genders 
and/or the effects of a different hormonal milieu [56]. With respect to the change in leptin 
levels according to menopausal status, data are inconsistent; some data have shown no 
change in leptin levels between the pre- and post-menopause [57], while other studies have 
demonstrated a decrease in leptin levels during the menopausal transition [58, 59]. Some 
investigators have suggested that the low amount of visceral fat compared with 
subcutaneous fat in the genders [60, 61] makes it unlikely that the leptin secretion rates from 
these two depots differ, and may therefore be the cause for the sexual dimorphism in leptin 
concentrations, suggesting an important role for sex steroid hormones [53]. According to 
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recent data derived from healthy pre- and post-menopausal women, postmenopausal 
women had increased levels of tissue plasminogen activator antigen (tPA), MCP-1, and 
adiponectin [24]. Furthermore, an increase in intraabdominal fat was correlated with C-
reactive protein, tPA, and leptin, and negatively with adiponectin levels. The results imply 
that during the menopausal transition, women have adverse changes in inflammatory 
markers and adipokines which correlate with increased visceral obesity. 
Several animal studies have indicated a stimulatory effect of estrogen on leptin expression 
and secretion in rat adipose tissues [59, 62]. Machinal et al. reported that there are 
regional differences in leptin expression between subcutaneous and deep fat tissues in 
rats, and that leptin secretion increased in the deep fat tissue tissues [63]. Based on one 
study involving human adipocytes, estrogen is likely to stimulate leptin expression [53]. 
In a previous study, the association between ER and adipokine expression in 3T3-L1 
adipocytes was investigated [64]. The results showed that ERǂ has a stimulatory effect on 
leptin expression, while the expression of ERǃ is inversely correlated with leptin 
expression. Therefore, discordant findings regarding the estrogen effect on leptin 
expression/secretion from other studies can be explained by the different expression of 
the two ER subtypes, which have opposite actions on the expression of leptin. In addition, 
if there are regulating factors (genetic or environmental) for ERǂ or ERǃ expression in 
adipocytes, this may explain how the different expression of ER in adipose tissue can 
affect the diverse obesity phenotypes. 
Adiponectin is a 30 kDa protein secreted abundantly from adipocytes [65, 66], and functions 
to exert anti-diabetic and anti-atherogenic properties. The serum adiponectin levels are 
decreased in obese individuals, metabolic syndrome, and type 2 DM [67, 68]. Similar to 
leptin, circulating adiponectin levels show a sexual dimorphism with higher levels in 
women than men [69]. Although the estrogen effects for adiponectin expression are limited, 
some in vitro studies have reported no direct regulatory effect in humans and mouse 
adipocytes [64, 70].   
Resistin is a cysteine-rich protein that was originally described as an adipose-derived 
protein in rodents that links obesity to insulin resistance [71]. However, in human data, the 
relationship of resistin with obesity and insulin metabolism is still debated. A widely 
reported biological role of resistin is the regulatory effect involved in inflammatory 
processes. In addition to adipocytes, resistin is induced by lipopolysaccharides and TNF-ǂ 
in macrophages [72]. The other data showed that resistin induces or is induced by IL-6 and 
TNF-ǂ via NF-κB in human monocytes [73, 74]. Data on estrogen effects for resistin 
expression are limited. In a mouse adipocyte model, the regulatory effect of 17ǃ-E2 on 
resistin expression is discordant [64, 75]. 
Recently described novel adipokines, such as visfatin, retinol binding protein-4, and 
omentin, have been shown to exert some metabolic properties, but their biological actions 
linked to obesity and interactions with estrogen need to be elucidated.       
6. Postmenopausal hormone therapy and change in body composition  
Hormone therapy (HT) is widely used for the treatment of menopausal symptoms and 
preventing bone loss in postmenopausal women. Estrogen replacement, when combined 
with various progestogens for endometrial protection, has been established as a 
conventional formulation. The benefit of HT is known to reduce vasomotor symptoms, 
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prevent osteoporotic fractures, and improve well-being and quality of life during the 
menopausal period. In contrast, the risks for breast cancer and thromboembolic disease may 
increase, and cardiovascular effects remain controversial.  
As previously mentioned, aging and menopause in women are related to an increase in 
body fat and redistribution of fat mass to the central portion of the body. These changes are 
linked to an increase in metabolic and cardiovascular disease after the menopause. 
Therefore, it has been continuously questioned and theorized that HT may have a favorable 
effect on change in body composition and anthropometries in postmenopausal women. 
With respect to this issue, data are still debated. In a meta-analysis of 24 RCTs, no effect of 
ET or HT on body weight was described [76]. However, subsequent studies suggested some 
beneficial effects of HT on body composition. A sub-study of the estrogen plus progestin 
trial of the Women’s Health Initiative (WHI) investigated whether or not postmenopausal 
HT affects age-related changes in body composition [77]. The WHI study was originally 
designed to evaluate the risks and benefits of HT (EPT/ET) with an enrollment of 16,608 
postmenopausal women between 1993 and 1998 [78]. The sub-analysis included 835 women 
who had whole-body dual-energy X-ray absorptiometry scans for measurement of body 
composition at baseline and year 3. Based on the results of the study, women who received 
EPT lost less lean soft tissue mass (-0.04 kg) than women who received placebo (-0.44 kg) 3 
year after intervention. Furthermore, less upper-body fat distribution was noted in the EPT 
group than the placebo group (ratio of trunk to leg fat mass, -0.025 for the EPT group and 
0.004 for the placebo group, P = 0.003). The investigators concluded that EPT has a 
favorable effect by reducing central fat deposition, but the real health benefits of this 
effect remains to be confirmed due to the small size of the effect. In a randomized, single-
blind study, the effects of HT on body fat composition were studied in 59 postmenopausal 
women (mean age 49.9 ± 3.8 years) [79]. The participants were assigned into the following 
three groups according to the type of HT: transdermal estradiol (E2)/norethisterone 
acetate (NETA); transdermal continuous E2/ oral medroxyprogesterone acetate (MPA); 
and oral continuous E2/NETA. The results showed that all types of HT caused a 
significant decrease in WC, subcutaneous fat, and WHR. Thus, HT reduced fat deposition 
in the central part of the body, and such an effect was more marked in women with a WC 
≥ 88 cm and subcutaneous fat ≥ 33 cm. Another placebo-controlled study investigated the 
effects of oral continuous E2/NETA on anthropometric changes and serum leptin levels in 
postmenopausal women [80]. In agreement with a previous study, WC and HC decreased 
significantly in the E2/NETA group, while the body weight (BW) increased in the placebo 
group. With this reduction in central fat deposition, the serum leptin levels were 
positively related to the changes in subcutaneous fat tissue. The authors advocated that 
HT may have a protective effect on CVD via a slimming effect on the central region in 
postmenopausal women.  
Although the effect of postmenopausal HT on the change of body composition is not clearly 
understood, the limited data have suggest that HT has a small, but significant effect on 
preventing an android fat shift (central fat depot) regardless of the body weight. 
Tibolone is a synthetic steroid hormone that exerts estrogenic, androgenic, and 
progestogenic properties. The biological actions of tibolone are mediated through the 
metabolites of tibolone (3ǂ-OH-tibolone, 3ǃ-OH-tibolone, and Δ4-isomer) by binding 
estrogen or progesterone receptors in multiple target tissues and organs (brain, bone, breast, 
and endometrium). Based on several randomized trials, tibolone has shown comparable 
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effects with traditional estrogen therapy (ET)/HT on relieving vasomotor symptoms/ 
genital atrophy, improving the quality of life, and preventing bone loss in postmenopausal 
women [81-84]. Currently 4 studies have shown the effects of tibolone on BW or body 
composition in postmenopausal women. In a 2-year follow up study comparing three 
regimens of HRT, tibolone had a stable effect on body fat and lean mass [85]. However, the 
fat mass increased (+3.6%) and the lean body mass decreased (-1.7%) in the control group. 
Another study demonstrated that tibolone significantly increased fat-free mass by 0.85 kg 
and total body water by 0.78 liter during a 1-year observation period [86]. The authors 
reported an effect of tibolone on preventing a decline in lean body mass, but mentioned the 
need for a long-term observational study.  
Arabi et al. compared the effects of tibolone with EPT (E2/NETA) on changes in body 
composition and bone densitometry in postmenopausal women [87]. Both EPT and 
tibolone increased lean body mass, whereas the android fat and android obesity index 
decreased.  
Tibolone might provide further benefits in increasing lean body mass and decreasing the fat 
component. Steroid hormones exert their action by binding to an intra-nuclear receptor [88]. 
Therefore, like estrogen, tibolone might have a direct effect on skeletal muscle by binding to 
ERǂ or ERǃ expressed within human skeletal muscle [88-90]. In addition, tibolone increases 
the serum IGF-1 levels [91], which promotes muscle protein synthesis, and increases the 
number of myogenic satellite cells and the proliferation of myogenic satellite cells. The 
anabolic effect of tibolone on muscle has been suggested to be mediated in part by local IGF-
1, independent of the serum IGF-1 level [92].   
7. Summary 
Adipose tissue is the largest endocrine organ in the human body. The amount and 
distribution of adipose tissue reflects energy balance. Adipose tissue also releases a variety 
of biologically active molecules or cytokines. Adipocyte metabolism and physiology have 
been extensively studied over recent years, but the exact mechanism and effect of sex steroid 
hormones involved in regulating adiposity remain to be defined.  
Current data give evidence that estrogen appears to have direct effects on cell proliferation 
or differentiation for adipocytes, and in regulating key enzymes involved in fat deposition. 
Another possible mechanism involves the hormonal or paracrine effects by secretion of 
various adipokines and cytokines, in which interactions with estrogen are promising and 
need additional studies.  
At present, it is not known whether or not HT provides a significant effect on modulating fat 
mass or preventing fat redistribution. Furthermore, in recent years the HT formulations 
have been changed to include lower doses of estrogen (< 50  μg) in combination with new 
progestins. The effects of the currently used HT regimens on changes in body fat 
composition are limited and require more data. Tibolone includes estrogenic, androgenic, 
and progestogenic properties which may affect the body composition (adipose tissue or lean 
mass) differently than conventional HT.  
The respective roles of sex steroid hormones and their receptors (ER subtypes and PR) on 
body fat distribution could be an interesting target for understanding the estrogen effect on 
adiposity, and may provide selective therapeutic approaches, such as hormonal 
manipulation for adiposity related to estrogen change throughout the menopausal period. 
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